Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Amarin Corporation PLC (AMRN) Stock Price
Press coverage about Amarin Corporation PLC (NASDAQ:AMRN) has trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Amarin Corporation PLC earned a daily sentiment score of 0.22 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 47.3584810302185 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Amarin Corporation PLC (AMRN) Downgraded by Zacks Investment Research (americanbankingnews.com)
- Amarin Corporation PLC (AMRN) Upgraded at ValuEngine (americanbankingnews.com)
- Amarin Corp. Plc :AMRN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017 (finance.yahoo.com)
- Equities Analysts Issue Forecasts for Amarin Corporation PLC’s FY2020 Earnings (AMRN) (americanbankingnews.com)
- Teeter-tottering Stocks: Yamana Gold Inc., (NYSE: AUY), SCANA Corporation, (NYSE: SCG), ImmunoCellular … – Stocks In The News (press release) (tradingnewsnow.com)
Shares of Amarin Corporation PLC (AMRN) traded up $0.04 during mid-day trading on Friday, hitting $3.60. The company had a trading volume of 1,360,544 shares, compared to its average volume of 1,217,773. Amarin Corporation PLC has a 52-week low of $2.76 and a 52-week high of $4.47. The company has a debt-to-equity ratio of -1.48, a current ratio of 1.63 and a quick ratio of 1.46.
Amarin Corporation PLC (NASDAQ:AMRN) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.01. The business had revenue of $47.10 million for the quarter, compared to the consensus estimate of $45.85 million. During the same period in the prior year, the business posted ($0.08) earnings per share. Amarin Corporation PLC’s revenue was up 45.4% on a year-over-year basis. research analysts expect that Amarin Corporation PLC will post -0.21 EPS for the current year.
AMRN has been the subject of several analyst reports. Zacks Investment Research raised Amarin Corporation PLC from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a research note on Tuesday, July 11th. BidaskClub lowered Amarin Corporation PLC from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. Jefferies Group LLC reissued a “buy” rating and set a $7.00 price target on shares of Amarin Corporation PLC in a research note on Thursday, August 3rd. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Amarin Corporation PLC in a research note on Thursday, August 3rd. Finally, ValuEngine lowered Amarin Corporation PLC from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $7.75.
In other Amarin Corporation PLC news, insider Steven B. Ketchum sold 63,479 shares of Amarin Corporation PLC stock in a transaction on Thursday, October 5th. The stock was sold at an average price of $3.48, for a total transaction of $220,906.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 3.72% of the company’s stock.
About Amarin Corporation PLC
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Receive News & Ratings for Amarin Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corporation PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.